11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Transient increases in urine albumin excretion are reported with short-term hyperglycemia, exercise, urine tract infections, sustained blood pressure elevation, heart failure, fever, and hyperlipidemia (451).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [451]
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [145]
In the citing paper
“Both the ADA and KDIGO recommend annual screening of patients with diabetes for CKD (17,18) (Fig. 1).”
In the citing paper
“This recommendation is based on strong evidence that SGLT2i reduce CKD progression, HF, and ASCVD risk in patients with T2D and CKD.”
In the citing paper
“These trials enrolled participants with albuminuria (ACR ≥300 mg/g and ≥200 mg/g, respectively); therefore, current evidence is strongest in this population, as emphasized by ADA recommendations (17) (Table 1).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · cited 1×
“Intensive glycemic control with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to delay the onset and progression of albuminuria and reduced eGFR in patients with type 1 diabetes (50,51) and type 2 diabetes (1,52 – 57).”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cited by
Items 301–349 of 349
Wang, Q., Huang, X., & Lu, W. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s432048
La progressione della malattia renale cronica
Manfellotto, D., & Pinna, G. (2023) · Italian Journal of Medicine · doi:10.4081/itjm.q.2023.3
Surawatsatien, N., Srisawat, N., & Pongsachareonnont, P. (2021) · doi:10.58837/chula.the.2021.93
Fernández, M. A. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art2
¿Cómo podemos realizar la protección renal del paciente con DM2?
Cuenca, A. M. C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art4
Tratamiento y seguimiento de personas con diabetes mellitus y enfermedad renal crónica
Bravo, J. J. M. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art7
Izquierdo, J. A. R. (2023) · Universidad Privada San Juan Bautista · doi:10.59590/upsjb/fcs.med.hum/tesis/4464
Ruidar, S. B., Wang, N., Tuerdi, A., & Fei, W. (2024) · doi:10.53555//jptcp.v31i1.4147
Pham, D. M., Nguyen, K. X., Viet, T. T., Le, T. D., Nguyen, N. P. T., Nguyen, N. M., Công, T. L., Nguyen, S. T., Nguyen, B. V., Nguyen, A. V., et al. (2024) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2023.32179
Viklický, O., Tesař, V., Rychlík, I., Prázný, M., Ryšavá, R., Češka, R., Haluzı́k, M., Ošťádal, P., Krejčí, J., & Táborský, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.008
Estimated glomerular filtration rate in elderly patients with type 2 diabetes
Żywiec, J., Klimczyk, K., Grzegorczyn, S. M., Łebek-Ordon, A., & Gołąb, A. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/186841
“In patients with risk factors for development of CKD, screening tests should be routinely performed, including determination of serum creatinine concentration and estimation of GFR as well as a urinalysis with the detection of albuminuria or overt proteinuria [8].”
BackgroundMethodSmetana, G. W., Romeo, G. R., Rosas, S. E., & Burns, R. B. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0764 · Cited by 2
“In 2022, the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) published consensus statements on the management of diabetes in CKD (3, 5).”
BackgroundChronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. E. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3452
Nur, R., Margarida, K., & Cale, W. (2024) · Journal of World Future Medicine Health and Nursing · doi:10.70177/health.v2i3.1046
“However, traditional approaches to chronic disease management are often not optimal in providing holistic and coordinated care (American Diabetes Association Professional Practice Committee, 2022).”
BackgroundSocial Drivers of Health Predict Annual Chronic Kidney Disease Screening & Disease DevelopmentPreprint
Ingle, M. E., Baman, S., Du, Y., Valuckaite, V., Singh, R., Kong, S. X., Williamson, T. E., & Khatib, R. (2024) · Research Square · doi:10.21203/rs.3.rs-5327718/v1
Comprehensive Study on Impact of Personalized Lifestyle Modification for Type 2 Diabetes Management
Raymond, A. M. (2024) · Med Discoveries · doi:10.52768/2993-1142/1208
Yang, Y., Zhang, X., Yin, Y., Wang, M., Xue, Y., Wang, H., & Zhao, T. (2025) · Medicine · doi:10.1097/md.0000000000041518
“[5,6] Furthermore, it is not recommended for diabetic patients without hypertension, albuminuria, and normal GFR, which limits its clinical use.”
Advances in understanding and managing diabetic kidney disease: An updated review
Habas, E. M., Rayani, A., Habas, A., Farfar, K., Habas, E., Alarbi, K. M. S., Habas, A. M., Errayes, E., & Alfitori, G. B. (2025) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(85).2025.09 · Cited by 1
Clinical Development of Treatment Direction for Diabetic Nephropathy as Diet and Pharmacotherapy
Ebe, K., Bando, H., & Wood, M. (2025) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2025/asjbccr.6391
Nghiên cứu hội chứng chuyển hóa -tim mạch- thận ở bệnh nhân đột quỵ não cấp
Quốc, H. T. Á. (2025) · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế · doi:10.38103/jcmhch.17.4.14
Finerenone in internal medicine and cardiology practice
Ječmenová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.044
Song, Z., Xu, H., Zhang, J., Liu, Y., Li, C., Chen, T., Guo, S., & Zhu, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1636392
Ortíz, A., Cebrián, A., Soto, A., Reyes, A., & Górriz, J. L. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501338
“The international clinical practice guidelines that were considered reference guidelines by the panelists' consensus, namely the KDIGO and ADA guidelines, 17,20 also reinforce this approach by covering all three treatment pillars.”
Narayan, J., Dixit, A., Sharma, R. B., & Tomer, S. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i9.7361
Zhang, T., Wang, X., Zhang, Y., Yang, Y., Yang, C., Wei, H., & Zhao, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26596457
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592413
Llauradó, G., Vlacho, B., Wargny, M., Ruan, Y., Franch‐Nadal, J., Domingo, P., Gourdy, P., Saulnier, P.-J., Hadjadj, S., Wild, S. H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21366003
Llauradó, G., Vlacho, B., Wargny, M., Ruan, Y., Franch‐Nadal, J., Domingo, P., Gourdy, P., Saulnier, P.-J., Hadjadj, S., Wild, S. H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21366009
Llauradó, G., Vlacho, B., Wargny, M., Ruan, Y., Franch‐Nadal, J., Domingo, P., Gourdy, P., Saulnier, P.-J., Hadjadj, S., Wild, S. H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21366006
Deravi, N., Sharifi, Y., Koohi, F., Zadeh, S. S. T., Masrouri, S., Azizi, F., & Hadaegh, F. (2024) · Figshare · doi:10.6084/m9.figshare.26577944
Pestka, D. L., Murphy, D. P., Huynh, P., Rechtzigel, J. A., Kjos, S., Ellich, L. M., Kaplan, A. N., Taylor, B. C., Atwood, M. A., Polsfuss, B. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26663458
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
Le-Nguyen, X.-D., Hoang, S. V., & Tran, N. Q. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s575757
“23 Serum glucose was determined by the hexokinase method.”
Liu, X.-Y., Zhao, Y., Zhang, Y.-G., Liu, Y., Wang, B.-Y., Hao, Z.-Z., & Hu, M.-H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1753126 · Cited by 1
López, L. V., Mendoza, M. F. F., Flores, A. V., Mafud, M. F. R., & la Peña, J. E.-D. (2026) · Nutrición Hospitalaria · doi:10.20960/nh.06423
kala, G. L., Sangeetha, R., & anjum, A. (2026) · International Journal of Novel Research and Development · doi:10.56975/ijnrd.v11i3.322373
The Cardiovascular Continuum Between Hypertension, Diabetes and Cardiovascular Disease
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7717-2
Youssry, S., Ghoneim, H., Ammar, Y., Srour, A. M., & Maharem, D. A. (2026) · BMC Immunology · doi:10.1186/s12865-026-00808-w
Endocan level and its association with glycemic and inflammatory indices in diabetic nephropathy
Al-Mayahi, L. M., & Shammaree, S. A. W. A. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02274-2
“• Adults aged ≥ 18 years with type 2 diabetes mellitus who were clinically diagnosed with diabetic nephropathy [28].”
Determinants of primary healthcare physicians’ knowledge of diabetic kidney disease
Fadili, W. (2026) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v18i1.5322
“8 Annual DKD screening is recommended by both the American Diabetes Association (ADA) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines, 9,10 and should start at diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes.”
InfluentialAlmohammadi, A. A., Alharbi, R. O., & Alhubayshi, S. S. (2025) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_33_25 · Cited by 2
PROTEIN-PROTEIN INTERACTION ANALYSIS TO IDENTIFY NEW DRUG TARGETS FOR DIABETES
Savitri, D. N., Syauqi, A., Naıbaho, N. M., & Muntasir, M. (2025) · Journal of Biomedical and Techno Nanomaterials · doi:10.70177/jbtn.v2i1.2023
“The network of protein interactions in the body is very complex and involves many interrelated biological pathways (American Diabetes Association Professional Practice Committee, 2022e).”
Major Adverse Kidney Events in the American Indian or Alaska Native Population with Diabetes
Zemke, A. M., Mayhand, K. N., Alicic, R. Z., Kornowske, L. M., Jones, C. R., Daratha, K. B., Reynolds, C., Nicholas, S. B., Petousis, P., Shpaner, L., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001121
Multifaceted roles of Isthmin-1 in health and disease: mechanism and therapeutic intervention
Wei, Y. M., Wu, W., Hou, Y., Zhang, Y., Zhao, K., & Ding, W. (2026) · Clinical Science · doi:10.1042/cs20260727
Zhang, K., Griffin, B. R., Chapman, J. B., & Soltys, M. D. (2026) · BMJ Open Quality · doi:10.1136/bmjoq-2026-004266
Zhao, H., Wang, Y., Du, Z., & Tian, L. (2026) · Archives of Medical Science · doi:10.5114/aoms/225401
“DKD was diagnosed according to KDIGO 2022 criteria [16] when UACR ≥ 30 mg/g was documented on at least 2 occasions ≥ 3 months apart (one prior, two at admission) or a reduced estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m².”
InfluentialShafi, T., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P. R., BRINKER, M. D., Rohwedder, K., Scott, C., Farag, Y. M. K., & Filippatos, G. S. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag299
Mishra, S., Ray, B., Guria, N. R., Bandyopadhyay, D., Mishra, A., & Mishra, S. K. (2026) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2026.1309000280
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S175-S184
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200340161
- Semantic Scholar
- 40f2cfa2d0038ac9f80bb94b8f8217ad1566bd6e
- Cited by
- 344
- References
- 112
- Citations by year
- 2026: 15 · 2025: 38 · 2024: 66 · 2023: 123 · 2022: 101 · 2021: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- chronic kidney disease, diabetes mellitus, risk management, clinical guidelines, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Renal Insufficiency, Chronic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.